R S de Jong
Overview
Explore the profile of R S de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Nes J, Seynaeve C, Maartense E, Roumen R, de Jong R, Beex L, et al.
Ann Oncol
. 2009 Oct;
21(5):974-82.
PMID: 19875752
Background: The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial investigates the efficacy and safety of adjuvant exemestane alone and in sequence after tamoxifen in postmenopausal women with hormone-sensitive early breast...
2.
Koopman M, Antonini N, Douma J, Wals J, Honkoop A, Erdkamp F, et al.
Ann Oncol
. 2006 Jul;
17(10):1523-8.
PMID: 16873425
Background: Results on overall survival in randomised studies of mono- versus combination chemotherapy in advanced colorectal cancer patients may have been biased by an imbalance in salvage treatments. This is...
3.
Hospers G, Schaapveld M, Nortier J, Wils J, van Bochove A, de Jong R, et al.
Ann Oncol
. 2006 Feb;
17(3):443-9.
PMID: 16500914
Background: A phase III study was started to compare oxaliplatin/5FU/LV in the first-line with bolus FU/LV in metastatic colorectal cancer. Patients And Methods: 302 patients were randomised and received bolus...
4.
Arends J, Sleeboom H, Leys M, Ten Bokkel Huinink D, de Jong R, Smit J, et al.
Br J Cancer
. 2005 Jan;
92(3):445-8.
PMID: 15668704
Advanced adenocarcinoma of the pancreas has a very poor prognosis. The aim of this study was to assess the efficacy and tolerability of a combination of the chemotherapeutic agents gemcitabine...
5.
Niamut S, de Vries P, van Putten J, de Jong R
Ned Tijdschr Geneeskd
. 2004 Oct;
148(38):1883-6.
PMID: 15497785
A 48-year-old woman with exanthema, pruritus and eosinophilia was found upon further examination to have a small-cell bronchus carcinoma; after chemotherapy and radiotherapy there was an almost complete response and...
6.
Seebus E, Vrugt B, de Jong R, Aalbers R
Eur Respir J
. 2003 Dec;
22(6):1042-5.
PMID: 14680097
No abstract available.
7.
de Jong R, Mulder N, Uges D, Sleijfer D, Hoppener F, Groen H, et al.
Br J Cancer
. 1999 Mar;
79(5-6):882-7.
PMID: 10070885
We conducted a phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin. Fostriecin was administered intravenously over 60 min on days 1-5 at 4-week intervals. Dose was...
8.
de Jong R, De Vries E, Meijer S, de Jong P, Mulder N
Cancer Chemother Pharmacol
. 1998 Jul;
42(2):160-4.
PMID: 9654117
Purpose: Fostriecin is an inhibitor of topoisomerase II catalytic activity. In a phase I trial we observed renal toxicity, documented as a rise in serum creatinine, which was reversible and...
9.
de Jong R, Hofstra L, Willemse P, de Bruijn H, De Vries E, Boonstra H, et al.
Gynecol Oncol
. 1997 Aug;
66(2):197-201.
PMID: 9264562
The effect of oral etoposide on CA-125 serum levels was evaluated in 17 patients with epithelial ovarian cancer and progressive disease during, or relapsing after, prior chemotherapy. Only three patients...
10.
de Jong R, De Vries E, Mulder N
Anticancer Drugs
. 1997 Jun;
8(5):413-8.
PMID: 9215602
Fostriecin is a novel antitumor antibiotic. In vitro studies showed that fostriecin inhibits DNA topoisomerase II (Topo II) catalytic activity, protein phosphatases involved with cell-cycle control and histone phosphatases. The...